文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

继续每周皮下注射司美格鲁肽对比安慰剂对超重或肥胖成人减重维持的影响:STEP 4随机临床试验

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

本研究为随机双盲3a期撤药试验,纳入902名超重或肥胖成人,经20周司美格鲁肽2.4 mg每周皮下注射导入后,803名达维持剂量者按2:1随机继续司美格鲁肽(n=535)或换安慰剂(n=268)治疗48周。主要终点为第20至68周体重变化百分比,继续治疗组为-7.9%,安慰剂组为+6.9%,差异-14.8个百分点(95%CI -16.0至-13.5;P<.001)。

要点

  • 超重/肥胖成人经20周司美格鲁肽2.4 mg导入减重10.6%后,继续治疗48周体重再降7.9%,换安慰剂则反弹6.9%。
  • 继续司美格鲁肽还改善腰围、收缩压和SF-36躯体功能评分,均优于安慰剂(P<.001)。
  • 胃肠道事件在继续治疗组更常见(49.1% vs 26.1%),但因不良事件停药比例相似(2.4% vs 2.2%)。

核心结论

  • 在完成20周司美格鲁肽2.4 mg每周皮下注射导入的超重或肥胖成人中,继续治疗相比换用安慰剂可在随后48周维持并进一步减重。

研究设计与样本

  • 随机、双盲、68周3a期撤药研究,于2018年6月至2020年3月在10个国家73个中心开展。
  • 纳入BMI≥30或≥27且伴至少1种体重相关合并症、无糖尿病的成人;902人接受导入治疗,803人(89.0%)达2.4 mg维持剂量后按2:1随机继续司美格鲁肽(n=535)或换安慰剂(n=268),两组均联合生活方式干预。

主要发现

  • 803名随机参与者平均年龄46岁(SD 12),女性634名(79%),平均体重107.2 kg(SD 22.7 kg),20周导入期平均减重10.6%。
  • 第20至68周平均体重变化:继续司美格鲁肽组-7.9%,换安慰剂组+6.9%,差异-14.8个百分点(95%CI -16.0至-13.5;P<.001)。
  • 继续司美格鲁肽组腰围变化-9.7 cm(95%CI -10.9至-8.5 cm),收缩压变化-3.9 mm Hg(95%CI -5.8至-2.0 mm Hg),SF-36躯体功能评分变化2.5(95%CI 1.6-3.3),均优于安慰剂(P<.001)。
  • 胃肠道事件发生率:继续司美格鲁肽组49.1%,安慰剂组26.1%;因不良事件停药比例分别为2.4%和2.2%。
  • 787名参与者(98.0%)完成试验,741名(92.3%)完成治疗。

临床怎么用

  • 对已耐受司美格鲁肽2.4 mg每周皮下注射并完成导入减重的超重或肥胖成人,继续治疗有助于维持减重效果并改善腰围、收缩压和躯体功能。
  • 需关注胃肠道不良事件,但因不良事件停药率与安慰剂相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown. OBJECTIVE: To compare continued once-weekly treatment with subcutaneous semaglutide, 2.4 mg, with switch to placebo for weight maintenance (both with lifestyle intervention) in adults with overweight or obesity after a 20-week run-in with subcutaneous semaglutide titrated to 2.4 mg weekly. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, 68-week phase 3a withdrawal study conducted at 73 sites in 10 countries from June 2018 to March 2020 in adults with body mass index of at least 30 (or ≥27 with ≥1 weight-related comorbidity) and without diabetes. INTERVENTIONS: A total of 902 participants received once-weekly subcutaneous semaglutide during run-in. After 20 weeks (16 weeks of dose escalation; 4 weeks of maintenance dose), 803 participants (89.0%) who reached the 2.4-mg/wk semaglutide maintenance dose were randomized (2:1) to 48 weeks of continued subcutaneous semaglutide (n = 535) or switched to placebo (n = 268), plus lifestyle intervention in both groups. MAIN OUTCOMES AND MEASURES: The primary end point was percent change in body weight from week 20 to week 68; confirmatory secondary end points were changes in waist circumference, systolic blood pressure, and physical functioning (assessed using the Short Form 36 Version 2 Health Survey, Acute Version [SF-36]). RESULTS: Among 803 study participants who completed the 20-week run-in period (with a mean weight loss of 10.6%) and were randomized (mean age, 46 [SD, 12] years; 634 [79%] women; mean body weight, 107.2 kg [SD, 22.7 kg]), 787 participants (98.0%) completed the trial and 741 (92.3%) completed treatment. With continued semaglutide, mean body weight change from week 20 to week 68 was -7.9% vs +6.9% with the switch to placebo (difference, -14.8 [95% CI, -16.0 to -13.5] percentage points; P < .001). Waist circumference (-9.7 cm [95% CI, -10.9 to -8.5 cm]), systolic blood pressure (-3.9 mm Hg [95% CI, -5.8 to -2.0 mm Hg]), and SF-36 physical functioning score (2.5 [95% CI, 1.6-3.3]) also improved with continued subcutaneous semaglutide vs placebo (all P < .001). Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo; similar proportions discontinued treatment because of adverse events with continued semaglutide (2.4%) and placebo (2.2%). CONCLUSIONS AND RELEVANCE: Among adults with overweight or obesity who completed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg once weekly, maintaining treatment with semaglutide compared with switching to placebo resulted in continued weight loss over the following 48 weeks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03548987.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID: 33755728. doi:10.1001/jama.2021.3224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。